Research Study

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Principal Investigator 
Michelle M. Mezei

Overview

Body Locations and Systems 
Neurologic Diseases
Disorders and Conditions 
Genetics
ClinicalTrials.gov# 
NCT01960348
Status 
Closed to Recruitment
Study Start/End 
May 14, 2015 to Dec 28, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Deborah Kraus, Research Nurse
Phone 
604-875-4405
Email Address 
deborah.kraus@vch.ca
Purpose of Study 

The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.